Name (Synonyms) | Correlation | |
---|---|---|
drug1849 | Placebo on a 0- and 14-day schedule Wiki | 1.00 |
drug1380 | Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki | 1.00 |
drug1057 | High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki | 1.00 |
drug2407 | T3 solution for injection Wiki | 1.00 |
drug1381 | Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki | 0.71 |
drug1058 | High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki | 0.71 |
drug1850 | Placebo on a 0- and 28-day schedule Wiki | 0.71 |
drug1458 | Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki | 0.71 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.
Description: Occurence of adverse reactions/events after vaccination
Measure: Adverse reactions/events rate Time: 7 days after vaccinationDescription: Occurence of adverse reactions/events after vaccination
Measure: Adverse reactions/events rate Time: 28 days after vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Occurence of Serious adverse events after vaccination
Measure: Serious adverse events Time: 12 months after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14
Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14
Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28
Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28
Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14
Measure: Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14
Measure: Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,14
Measure: Level of anti-N protein antibodies Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,14
Measure: Level of anti-N protein antibodies Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28
Measure: Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28
Measure: Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,28
Measure: Level of anti-N protein antibodies Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,28
Measure: Level of anti-N protein antibodies Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase Ia immunization schedules
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (both schedules) Time: 3, 6, 9 and 12 months after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase IIa immunization schedules
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (both schedules) Time: 6 and 12 months after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase Ia immunization schedules
Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (both schedules) Time: 3, 6, 9 and 12 months after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase IIa immunization schedules
Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (both schedules) Time: 6 and 12 months after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,14
Measure: Cellular immune responses Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,14
Measure: Cellular immune responses Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,28
Measure: Cellular immune responses Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,28
Measure: Cellular immune responses Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccination